SIGA to Present ST-246 to the World Health Organization Nov 12, 2008
Source: SIGA Technologies, Inc. ... NEW YORK, Nov. 12, 2008 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NasdaqCM: - ), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens today announced that Dr. Dennis E. Hruby, SIGA's Chief Scientific Officer, will be presenting SIGA's progress in developing its lead drug candidate, ST-246, an antiviral for smallpox and other orthopoxviruses, to the World Health Organization (WHO) Advisory Committee on Variola... (Primezone Releases)
SIGA Technologies to Participate in Committee Meeting for the Institute of Medicine Sep 25, 2008
Source: SIGA Technologies, Inc. ... NEW YORK, Sept. 25, 2008 (GLOBE NEWSWIRE) -- SIGA Technologies (NasdaqCM: - ), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, today announced that Dr. Dennis E. Hruby, Chief Scientific Officer, will be participating as an outside expert in the committee evaluating the research and development work recommended in the Institute of Medicine's 1999 report, Assessment of Future Scientific Needs for Live Variola... (Primezone Releases)
Here’s a list of local issues that have been covered recently in the Gazette-Times and the status of those stories: (51) Sep 21, 2008
Story so far: Siga Technologies, a Corvallis research lab, is developing drugs to combat everything from emerging infectious diseases to bioterror weapons. The latest: The company announced two new federal research grants last week. (Corvallis Gazette Times, OR)
Local lab lands $20 million for research (72) Sep 19, 2008
Siga Technologies continues to bolster its revenue stream with federal biodefense dollars ... Siga Technologies is headquartered in New York but operates laboratory facilities in Corvallis, where it employs about 50 people. (Corvallis Gazette Times, OR)
NIH Funds SIGA Dengue Antiviral Program Sep 12, 2008
Source: SIGA Technologies, Inc. ... NEW YORK, Sept. 12, 2008 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NasdaqCM: - ), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens and emerging human health threats, today announced the receipt of a Small Business Innovation Research Advanced Technology Phase I grant from the National Institute of Allergy and Infectious Disease (SBIR-AT-NIAID) ... About SIGA Technologies, Inc.. (Primezone Releases)
Siga lands $55 million for research Sep 4, 2008
Siga Technologies Inc. announced Wednesday that it has been awarded 55 million to expand development work on a treatment for smallpox ... Siga Technologies, which is headquartered in New York City and employs about 50 people at its Corvallis laboratories, has been working on a smallpox treatment for several years in partnership with the government. (Corvallis Gazette Times, OR)
SIGA Technologies to Announce Second Quarter 2008 Results of Operations on August 12, 2008 Aug 5, 2008
Source: SIGA Technologies, Inc. ... NEW YORK, Aug. 5, 2008 (PRIME NEWSWIRE) -- SIGA Technologies, Inc. (NasdaqCM: - ), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, plans to announce its second quarter 2008 results in a press release that will be issued on Tuesday, August 12, 2008 before the market open ... Participants should call 877-419-6590 (United States/Canada) or 719-325-4887 (International) and request the SIGA Technologies call or... (Primezone Releases)
Editorial: Econ vitality key to bioscience future (July 24) Jul 24, 2008
A partial list includes companies such as Synthetech, Oregon Freeze Dry, Gene Tools, Tec Labs, AVI BioPharma and Siga Technologies. Oregon State University, Linn-Benton Community College and other colleges and universities in the area offer a pool of graduates in science, engineering and business. (Corvallis Gazette Times, OR)
Bioscience industry tackles its challenges Jul 20, 2008
Casey Campbell/Gazette-TimesSiga Technologies is part of a burgeoning bioscience cluster in the mid-valley ... A core of established firms such as Synthetech, Tec Labs and Oregon Freeze Dry in Albany, AVI BioPharma and Siga Technologies in Corvallis, Gene Tools in Philomath and Invitrogen in Eugene. (Corvallis Gazette Times, OR)
New Single-Dose Orthopoxvirus Drug In First Stage Of Human Trials May 27, 2008
ScienceDaily (May 27, 2008) Researchers from SIGA Technologies, TransTech Pharma, and INC Research developed a new single-dose antiviral drug against orthopoxvirus that was safely tolerated in humans during phase I trials and could potentially be used to prevent and treat smallpox. See also. (Science Daily)
Tips from the Journals of the American Society for Microbiology May 23, 2008
Researchers from SIGA Technologies, TransTech Pharma, and INC Research developed a new single-dose antiviral drug against orthopoxvirus that was safely tolerated in humans during phase I trials and could potentially be used to prevent and treat smallpox. They report their findings in the May 2008 issue of the journal Antimicrobial Agents and Chemotherapy. (EurekAlert!)
Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthene's Legal Action in Breach of Contract Lawsuit Against SIGA Jan 17, 2008
Jan. 16 /PRNewswire-FirstCall/ -- PharmAthene, Inc., (Amex: ) a biodefense company developing medical countermeasures against biological and chemical threats, announced that the Delaware Chancery Court today issued a ruling denying a motion by SIGA Technologies to dismiss PharmAthene's complaint, which alleges that it has a right to an exclusive license to develop and market SIGA's drug candidate, SIGA-246. SIGA's request to dismiss the claim by PharmAthene was denied in all respects by the... (PR Newswire)
SIGA Completes 21 Day Multi-Dose Human Clinical Safety and Dose-Ranging Trial of Its Lead Smallpox Drug ST-246 Dec 6, 2007
Source: SIGA Technologies ... NEW YORK, Dec. 6, 2007 (PRIME NEWSWIRE) -- SIGA Technologies, Inc. (NasdaqCM: - ), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens and protect the population at large, today announced that its lead drug candidate, ST-246, has successfully completed another human clinical trial ... About SIGA Technologies, Inc.. (Primezone Releases)
Market Pulse Announces Its AM Stock Picks for Friday, September 28, 2007: CMG, SPKL, INTC, SIGA Sep 28, 2007
SIGA Technologies Inc. (NasdaqCM: - ): Attractive. ADVERTISEMENT. (Primezone Releases)
Sirius Satellite Radio Inc. Tops Deloitte's New York Technology Fast 50 Ranking of Fastest Growing Companies With 79,060 Percent Revenue Growth Over Five Years Sep 21, 2007
The New York Technology Fast 50 company ranking is as follows: Ranking Company City/Town CEO Type 1 Sirius Satellite New York Mel Karmazin Media and Radio Inc. Entertain- ment 2 Orchestria Inc. New York Bo Manning Software 3 Didit Rockville Centre Kevin Lee Internet 4 Acclaro Inc. Irvington Michael Kriz Software 5 The Orchard New York Greg Scholl Media/ Entertain- ment 6 Juma Technology Farmingdale David Communi- Corporation Giangano cations and Net- working 7 Vibrant Media, New York Doug Media/... (Yahoo! Wire -- Entertainment News)
Toddler survives smallpox vaccine reaction May 18, 2007
The treatments included an antiviral drug made by Siga Technologies Inc., vaccinia immune globulin and the antiviral drug cidofovir, made by Gilead Sciences Inc.. The child's mother also had a rash, which went away after she got immune globulin, a treatment made from the blood of vaccinated people. (Scientific American)
New drug aids child sickened by dads shot Apr 14, 2007
Hruby, now chief scientific officer of Siga Technologies Inc., did some of the basic research at Oregon State University decades ago that laid the groundwork for Sigas experimental smallpox drug SIGA-246. The drug, which has been proven to work in primates infected with smallpox and monkeypox, was one of several treatments used on the child. (MSNBC -- Health)
Child in hospital after father's smallpox vaccination Mar 21, 2007
The child has been treated with immune globulin, an antiviral drug called cidofovir, and an experimental antiviral made by Siga Technologies called SIGA-246, Damon said. "We are cautiously optimistic that the child is improving," Damon said. (Scientific American)
Celebrate Corvallis spreads out Jan 23, 2007
Dennis Hruby, Siga Technologies. Tammy VanVleet, PEAK Elite. (Corvallis Gazette Times, OR)
Arundel company gains a partner Jan 23, 2007
Less than a year ago, PharmAthene had planned to merge with another publicly traded company, SIGA Technologies Inc., which would have bought a third of PharmAthene's shares and provided $3 million in interim financing, not to mention a ticker symbol on the Nasdaq stock market. The New York City-based company was developing a smallpox vaccine and other biodefense products, which would have made it a good match for PharmAthene. (Sunspot.net -- Business)
PharmAthene taps new CFO Jan 9, 2007
Last year, PharmAthene announced plans to merge with New York-based SIGA Technologies Inc., a publicly held company. The merger was designed to allow privately held PharmAthene to go public by merging with a smaller public firm. (Washington Business Journal, DC)
